# Influenza Vaccine

**High-Dose Trivalent Inactivated**

**Implementation: September 1, 2020**

Please consult the Product Monograph¹ for further information about the vaccine.

<table>
<thead>
<tr>
<th><strong>Manufacturer</strong></th>
<th>Sanofi Pasteur Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Licensed use</strong></td>
<td>65 years of age and older</td>
</tr>
<tr>
<td><strong>Off-license use</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Indications for use of provincially funded vaccine</strong></td>
<td>65 years of age and older residing in a provincially funded Long-Term Care bed in auxiliary hospitals and nursing homes. Note: If a facility with Long Term Care funded beds also has Designated Supportive Living beds, those residents 65 years of age and older can also be offered Fluzone® High Dose vaccine.</td>
</tr>
<tr>
<td><strong>Influenza strains for 2019-2020 season</strong></td>
<td>A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus ¹,² A/Hong Kong/2671/2019 (H3N2)-like virus ¹,² B/Washington/02/2019 (B/Victoria lineage)-like virus ¹,²</td>
</tr>
<tr>
<td><strong>Dose</strong></td>
<td>0.5 mL¹</td>
</tr>
<tr>
<td><strong>Route</strong></td>
<td>Intramuscular injection</td>
</tr>
<tr>
<td><strong>Schedule</strong></td>
<td>1 dose</td>
</tr>
<tr>
<td><strong>Contraindications</strong></td>
<td>Known severe hypersensitivity to any component of the vaccine with the exception of egg ³ (see Precautions below). Anaphylactic or other allergic reaction to a previous dose of influenza vaccine.¹,³ Avoiding subsequent immunization of individuals known to have had Guillain-Barré Syndrome (GBS) within six weeks of a previous influenza immunization appears prudent at this time.¹,³ However, the potential risk of GBS recurrence associated with influenza vaccine must be balanced against the risk of GBS associated with influenza infection itself and the other benefits of influenza immunization.¹,³ The relative and attributable risks of GBS after seasonal influenza immunization are lower than those after influenza illness.⁴</td>
</tr>
<tr>
<td><strong>Precautions</strong></td>
<td>Egg-allergic individuals may be immunized against influenza using inactivated vaccine without a prior influenza vaccine skin test and with the full dose of vaccine, irrespective of a past severe reaction to egg.³ Egg-allergic vaccine recipients should be kept under observation for 30 minutes following the administration of inactivated influenza vaccine. Expert review of the risks and benefits of influenza immunization should be sought for individuals who previously experienced severe lower-respiratory symptoms (wheeze, chest tightness, difficulty breathing) within 24 hours of influenza immunization, an</td>
</tr>
</tbody>
</table>

¹ Out of date
Individuals who have experienced oculorespiratory syndrome (ORS) including those with a severe presentation (bilateral red eyes, cough, sore throat, hoarseness, facial swelling) but without lower respiratory tract symptoms, may be safely re-immunized. Advice of an expert should be sought before immunizing individuals who experienced ORS with lower respiratory tract symptoms.

Although influenza vaccine can inhibit the clearance of warfarin and theophylline, clinical studies have not shown any adverse effects attributable to these drugs in people receiving influenza vaccine.

Possible reactions

See Product Monograph

Pregnancy

Not applicable

Lactation

Not applicable

Program Notes

- 1992 (approx.): Influenza vaccine split virus Influenza split virus vaccine first used in Canada in approximately 1992. (Fluviral® & Vaxigrip®)
- 2009-2010: Influenza vaccine for H1N1 Pandemic universal program for everyone six months of age and older. Start of the universal influenza program.
- 2015-2016: Flumist® Quadrivalent, Fluviral, Influvac® (adults 18 to 64 years of age), Fluad® (all Albertans aged 65 years and older)
- 2016-2017: Fluzone®, Fluad®, Flumist®
- 2017-2018: Fluzone®, Fluad® (long term care and supportive living only)
- 2018-2019: Fluzone®, FluLaval® Tetra
- 2019-2020: Fluzone®, FluLaval® Tetra

References

1 Sanofi Pasteur Inc. (2020). Fluzone® High-Dose Influenza virus vaccine Trivalent Types A and B (Split Virion). Product Monograph.

